News

Scott T. Tagawa, MD, discusses the potential of sacituzumab govitecan in advanced urothelial cancers and reflects on progress made in prostate cancer.

Douglas A. Nelson, MD, discusses key advances made in the treatment of patients with colorectal cancer and pancreatic cancer, and sheds light on remaining challenges in these paradigms.

Raoul S. Concepcion, MD, FACS, discusses the clinical implications of the findings from the ARAMIS trial and highlights other therapies that are coming down the pike for the treatment of patients with castration-resistant prostate cancer.

The European Medicine Agency’s Committee for Medicinal Products for Human Use has granted a positive opinion to olaparib tablets as monotherapy for the treatment of adult patients with germline BRCA1/2-mutant, HER2-negative locally advanced or metastatic breast cancer.

Erika P. Hamilton, MD, shares insight on the management of patients with HER2-positive breast cancer and strategies aimed at targeting treatment resistance and toxicity.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of lorlatinib for the treatment of adult patients with ALK-positive advanced non–small cell lung cancer whose disease has progressed after alectinib or ceritinib as the first ALK TKI, or crizotinib and at least one other ALK TKI.

Mirvetuximab soravtansine did not improve progression-free survival compared with chemotherapy in patients with folate receptor alpha–positive, platinum-resistant ovarian cancer and in an overall patient population, missing the primary endpoint of the phase III FORWARD I trial.

The FDA has expanded the approval of aprepitant injectable emulsion to include a 2-minute intravenous use for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.

The FDA has approved subcutaneous use of trastuzumab and hyaluronidase-oysk injection in combination with chemotherapy for the treatment of select patients with HER2-positive early breast cancer, in combination with paclitaxel in patients with metastatic HER2-positive breast cancer as a frontline treatment, and alone for patients with metastatic disease who have received at least 1 prior chemotherapy regimen

Brandon Smaglo, MD, highlights investigational treatment approaches for patients with gastric cancer and calls for further research in the adjuvant setting to move the needle forward.

A new drug application has been filed with the FDA for darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer. ​

Joseph F. Stilwill, MD, shares insight on the clinical benefit seen with CDK4/6 inhibitors in patients with advanced HR-positive, HER2-negative breast cancer and highlights ongoing research aimed at overcoming acquired resistance.

Leo I. Gordon, MD, discussed these recent updates in Hodgkin lymphoma and non–Hodgkin lymphoma and pointed to research on the horizon.

The FDA’s Oncologic Drugs Advisory Committee voted against accelerated approval of a new drug application for selinexor for the treatment of patients with penta-refractory multiple myeloma, recommending delaying a decision on the drug until results are available from the pivotal phase III BOSTON trial.

The FDA has granted a priority review designation to a supplemental new drug application for the R2 regimen of lenalidomide (Revlimid) plus rituximab (Rituxan) for use in patients with previously treated follicular lymphoma and marginal zone lymphoma.

Frontline maintenance therapy with olaparib significantly reduced the risk of disease progression or death versus placebo in patients with germline BRCA-mutated metastatic adenocarcinoma of the pancreas, according to findings from the phase III POLO trial.

The combination of the PD-1 inhibitor pembrolizumab and platinum/taxane chemotherapy in the neoadjuvant setting induced high rates of pathologic complete response in patients with locally advanced triple-negative breast cancer.

Matthew H.G. Katz, MD, FACS, highlights pivotal trials in pancreatic cancer and how these data are shifting the treatment paradigm for these patients.

A subcutaneous formulation of daratumumab is noninferior in inefficacy and pharmacokinetics compared with standard intravenous daratumumab in patients with relapsed/refractory multiple myeloma.

Daniel M. Halperin, MD, sheds light on the latest research in neuroendocrine tumors.

Jane L. Meisel, MD, discusses recent breakthroughs in the previously stagnant field of triple-negative breast cancer and what these advances mean for patients.

Michael Overman, MD, highlights data from pivotal trials presented at the 2019 Gastrointestinal Cancers Symposium and discusses where research efforts should be focused to improve the treatment of patients with colorectal cancer.

The Association of Community Cancer Center's 45th Annual Meeting and Cancer Center Business Summit prepares oncology stakeholders for dramatic transformations in cancer care delivery.

The FDA has approved TAS-102 (trifluridine/tipiracil; Lonsurf) for adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least 2 prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

Sumit K. Subudhi, MD, PhD, discusses the promise of the combination of nivolumab and ipilimumab in patients with metastatic castration-resistant prostate cancer and the challenges that lie ahead with this treatment approach.